{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:03:59Z","timestamp":1789916639830,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,5,24]],"date-time":"2002-05-24T00:00:00Z","timestamp":1022198400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p><jats:bold>Summary:<\/jats:bold><jats:bold> \u2002Purpose: <\/jats:bold> To assess the efficacy and safety of levetiracetam (LEV) as adjunctive therapy in children with treatment\u2010resistant partial\u2010onset seizures.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Children (aged 6\u201312 years) with treatment\u2010resistant partial\u2010onset seizures receiving one standard antiepileptic drug (AED) were eligible. After a 4\u2010week baseline period, children received LEV in a 6\u2010week titration phase (target dose, 40 mg\/kg\/day) followed by an 8\u2010week evaluation phase. Seizure frequency during the evaluation period with individualized LEV doses (20\u201340 mg\/kg\/day) were compared with the 4\u2010week baseline seizure frequency. Plasma concentrations of LEV and other AEDs were determined to evaluate potential drug interactions.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty\u2010four subjects enrolled and received LEV; 23 entered the evaluation phase, and 22 completed the evaluation phase. Compared with their baseline seizure frequency, 12 (52%) of 23 subjects entering the evaluation phase had their seizure frequency decrease by &gt;50%. Two subjects remained seizure free during the entire evaluation period. LEV did not significantly affect plasma concentrations of any concomitant AED during this study, and no alteration of mean clinical laboratory values was observed. The most commonly reported adverse events were headache, infection, anorexia, and somnolence.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This open\u2010label study of adjunctive LEV therapy (at 20\u201340 mg\/kg\/day) suggests that LEV is effective, safe, and well tolerated in children ages 6\u201312 years with treatment\u2010resistant partial\u2010onset seizures. A randomized, placebo\u2010controlled, double\u2010blind trial of LEV adjunctive therapy in children with treatment\u2010resistant partial\u2010onset seizures is needed and ongoing to confirm these open\u2010label findings.<\/jats:p>","DOI":"10.1046\/j.1528-1157.2002.13101.x","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T21:39:22Z","timestamp":1027892362000},"page":"518-524","source":"Crossref","is-referenced-by-count":138,"title":["Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open\u2010label\u2003Trial"],"prefix":"10.1111","volume":"43","author":[{"given":"Tracy\u2003A.","family":"Glauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John\u2003M.","family":"Pellock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.\u2003Martina","family":"Bebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan\u2003B.","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank\u2003J.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof\u2003M.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.\u2003Donald","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,5,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.11.1785"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91123-R"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2292"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02513.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02920.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9091(97)80007-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1684"},{"issue":"4","key":"e_1_2_6_9_2","first-page":"S74","article-title":"Topiramate: pooled analysis of six placebo\u2010controlled trials.","volume":"37","author":"Reife R","year":"1996","journal-title":"Epilepsia"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9091(97)80006-X"},{"key":"e_1_2_6_11_2","first-page":"1011","volume-title":"Antiepileptic drugs","author":"Seino M","year":"1995"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb03702.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb05201.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb05199.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320313"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1282"},{"key":"e_1_2_6_17_2","first-page":"61","article-title":"Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy.","volume":"35","author":"Steiner TJ","year":"1994","journal-title":"Epilepsia"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1018"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01120.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb06011.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01013-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00024-7"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(89)90070-3"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00833.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.8.1724"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2237"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1338"},{"key":"e_1_2_6_28_2","first-page":"1205","volume-title":"Epilepsy: a comprehensive textbook","author":"Pellock JM","year":"1997"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.5.1106"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00043-7"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.41300.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(99)00011-9"},{"key":"e_1_2_6_37_2","first-page":"426","article-title":"Levetiracetam, a pyrrolidone drug recently licensed as an antiepileptic.","volume":"72","author":"Shorvon SD","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01079.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1528-1157.2002.13101.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1528-1157.2002.13101.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T05:22:15Z","timestamp":1697347335000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1528-1157.2002.13101.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1046\/j.1528-1157.2002.13101.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1528-1157.2002.13101.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}